Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0403608 (
ureter
)
9,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Protein kinase C-related kinases are regulated by phosphatidylinositol-3-kinase and Rho family GTPases. The isoform
PRK1
has been characterized in detail in prostate cancer, but not in other carcinomas. We analyzed our prior microarray data for
PRK1
gene expression in 175 carcinomas and evaluated tissue microarrays for protein expression in 251 carcinomas and a comprehensive group of normal tissues. We also used immunoblotting to determine the levels and phosphoactivation status of
PRK1
, PRK2, and PDK1 in 12 ovarian serous carcinomas, SKOV3 cells, and 3 samples of normal ovarian surface epithelium (OSE). The highest average level of
PRK1
messenger RNA was observed in ovarian serous carcinomas compared with all other carcinomas, including those of the prostate, bladder/
ureter
, breast, colon, stomach/esophagus, kidney, liver, pancreas, and lung (P = .05). By immunohistochemistry,
PRK1
was observed in selected normal cells, including epithelium from the gynecologic tract and hematolymphoid elements. All serous ovarian and endometrial endometrioid adenocarcinomas and mesotheliomas were immunoreactive for
PRK1
. The findings in nonserous ovarian and most carcinomas from the prostate, breast, and pancreas were also positive but less consistently so. In comparison with OSE, the serous carcinomas typically had greater pPRK1/total
PRK1
(P = .02) as well as greater pPDK/total PDK (P = .01). The relative phosphorylation status of these 2 kinases correlated within each sample. In summary,
PRK1
is present in various malignancies, but especially in serous carcinomas, where the increased activation status of
PRK1
and its upstream regulator, PDK, as compared with normal OSE suggests a role in ovarian cancer development or progression.
...
PMID:PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. 1942 17